Klotho Neuroscience Inc.

06/11/2025 | Press release | Distributed by Public on 06/11/2025 04:04

Material Agreement, Private Placement (Form 8-K)

Item 1.01 Entry into a Material Definitive Agreement

On June 10, 2025, Klotho Neurosciences, Inc. (the "Company") amended its April 2022 Public Warrant (the "Amended Warrant") to provide for a one-time, limited time repricing of the exercise price (the "Warrant Repricing").

Pursuant to the Warrant Repricing, the terms of the Public Warrant were amended to reduce the exercise price of the Public Warrants to $1.35 during the time period commencing at 9:30 AM on June 10, 2025 Eastern Time until 4:00 PM on June 20, 2025 Eastern Time (the "Effective Date Range"). In the event that a Public Warrant is not exercised during the Effective Date Range, the exercise price reverts to the exercise price in effect prior to the Effective Date Range, which was $3.49.

Holders of Public Warrants who desire to exercise their Public Warrant should contact their stock broker.

The foregoing summary of the Amended Warrant does not purport to be complete and is subject to, and qualified in its entirety by, such document attached as Exhibit 4.1 to this Current Report on Form 8-K, which are incorporated herein by reference.

Item 3.02 Unregistered Sales of Equity Securities

The Company reported earlier that on June 5, 2025, the Company entered into a Stock Purchase Agreement for the purchaser of shares of the Company's common stock for a total purchase price of $500,000. The earlier report misstated the number of shares purchased and should have to stated such number as 6,250,000.

The sale listed above was made in reliance upon the exemption from registration offered by Section 4(2) of the Securities Act of 1933 and based upon the pre-existing relationship between the Registrant and the purchaser, the Registrant had reasonable grounds to believe immediately prior to making an offer to such individual, and did in fact believe, that such individual (1) was purchasing for investment and not with a view to distribution, and (2) had such knowledge and experience in financial and business matters that he was capable of evaluating the merits and risks of his investment and was able to bear those risks. An appropriate restrictive legend is imprinted upon the certificates representing such shares, and stop-transfer instructions have been entered in the Registrant's transfer records. All such sales were effected without the aid of underwriters, and no sales commissions were paid.

Klotho Neuroscience Inc. published this content on June 11, 2025, and is solely responsible for the information contained herein. Distributed via SEC EDGAR on June 11, 2025 at 10:04 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at support@pubt.io